Oxfordshire, UK, 27 April 2020 – Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2507 Phase I study at the American Association for Cancer Research (AACR) Annual Meeting 2020.
The Phase I clinical trial, conducted at The University of Texas MD Anderson Cancer Center, examined the safety, tolerability, pharmacokinetic properties and pharmacodynamic effects of KA2507 in patients with advanced cancer for whom no standard of care therapy was available. KA2507 was well tolerated at all doses tested, and there was evidence of selective target engagement at all exposure levels.
KA2507, an orally active drug, is a potent and highly selective inhibitor of histone deacetylase 6 (HDAC6). HDAC6 is an attractive therapeutic target, and its inhibition has the potential to disrupt cancer signalling pathways and increase the activity of the immune system against the tumour.
Tim Edwards, Karus’ Executive Chairman, commented:
“These new findings represent an important step forward in our mission to develop new precision medicines for cancer patients. They show that KA2507 is largely free from significant side effects and free from the toxicities that have limited the development of other less selective HDAC inhibitors. KA2507 is now ready to be taken to the next stage of clinical development, possibly in combination with immunotherapy."
Details of the poster presentation are as follows:
Title: Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors.
Abstract number: 10141
Time and Date: April 27, 2020, 9:00 AM - 6:00 PM (US EDT)
Session Type: Poster Session
Session Title: Phase I Clinical Trials: Part 2
Presenter: Apostolia Maria Tsimberidou, MD, PhD (on behalf of MD Anderson Cancer Center)
About Karus Therapeutics
Karus Therapeutics, based in Oxfordshire, UK, is a clinical-stage biopharmaceutical company developing precision medicines for cancer. The Company’s orally-active, small molecule drugs combine targeted and immunotherapeutic mechanisms of action for the treatment of cancer patients with clear unmet medical need and limited treatment options. Karus has two small molecule clinical candidates which have substantially completed Phase I studies, KA2507 and KA2237. The Company is privately-held and is supported by a world-leading syndicate of life science investors from the US and Europe: SV Health Investors, New Leaf Ventures, Novo A/S and IP Group.
For further information please visit: www.karustherapeutics.com
Issued for and on behalf of Karus Therapeutics by Instinctif Partners.
For more information please contact: firstname.lastname@example.org